EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON BLEEDING-TIME, PLATELET NUMBER AND FUNCTION IN CHILDREN WITH END-STAGE RENAL-DISEASE MAINTAINED BY HEMODIALYSIS

被引：31

作者：

FABRIS, F

CORDIANO, I

RANDI, ML

CASONATO, A

MONTINI, G

ZACCHELLO, G

GIROLAMI, A

机构：

[1] Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua

[2] Department of Paediatrics, University of Padua Medical School, Padua

来源：

PEDIATRIC NEPHROLOGY | 1991年 / 5卷 / 02期

关键词：

RECOMBINANT HUMAN ERYTHROPOIETIN; CHRONIC RENAL FAILURE; BLEEDING TIME; PLATELET AGGREGATION; THROMBOXANE-B2; PLATELET VOLUME;

D O I：

10.1007/BF01095958

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We studied platelet number and function in nine anaemic children with end-stage renal disease during a clinical trial with recombinant human erythropoietin (rHu-EPO). All the children showed a correction in both haematocrit and haemoglobin levels which was followed by a significant reduction in bleeding time. We also observed a significant increase in platelet count after both 6 and 12 weeks of therapy; at the same time mean platelet volume decreased and a normal platelet mass was maintained. The mean baseline platelet aggregation response to ADP was normal, but was decreased to collagen (P < 0.05 vs normal control). Platelet production of thromboxane B2 in serum was also lower than normal controls. After correction of anaemia with rHu-EPO, platelet aggregation improved in patients with a decreased baseline response, and mean levels of thromboxane B2 became normal. In conclusion, the treatment with rHu-EPO improved haemostatic balance not only by correcting anaemia, but also by increasing platelet count and function.

引用

页码：225 / 228

页数：4

共 23 条

[1]

Eschbach J.W., The anaemia of chronic renal failure, pathophysilogy and the effects of recombinant human erythropoietin, Kidney Int, 35, pp. 134-148, (1989)

[2]

Eschbach J.W., Egrie J.G., Dowing, Browne J.K., Adaon J.W., Correction of anaemia of end-stage renal disease with recombinant human erythropoietin: results of combined stage I and II clinical trial, N Engl J Med, 316, pp. 73-78, (1987)

[3]

Livio M., Gotti E., Marchesi D., Mecca G., Remuzzi G., De Gaetano G., Uremic bleeding: role of anaemia and beneficial effect of red-cell transfusions, Lancet, 2, pp. 1013-1015, (1982)

[4]

Moia M., Vizzotto L., Cattaneo M., Mannucci P.M., Casati S., Ponticelli C., Improvement in the haemosstatic defect of uremia after treatment with recombinant human erythropoietin in anaemic patients on hemodialysis, Lancet, 1, pp. 73-78, (1987)

[5]

Steiner R.W., Coggins C., Carvalho A.C.A., Bleeding time in uremia: a useful test to assess clinical bleeeding, Am J Hematol, 17, pp. 107-117, (1979)

[6]

Woolley A.C., Platelet dysfunction in uremia, Kidney, 19, pp. 15-19, (1987)

[7]

Remuzzi G., Bleeding in renal failure, Lancet, 1, pp. 1205-1208, (1988)

[8]

Di Minno S., Martinez J., McKean M.L., De La Rosa J., Burke J.F., Murphy S., Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis, Am J Med, 79, pp. 552-559, (1985)

[9]

Fabris F., Randi M.L., Sbrojavacca R., Casonato A., Girolami A., The possible value of platelet aggregation studies in patients with increased platelet number, Blut, 43, pp. 279-285, (1981)

[10]

Luzzatto G., Fabris F., Mazzucato M., Girolami A., PF4 versus BTG as evidence for platelet activation in myeloproliferative disorders, Scand J Haematol, 35, pp. 299-304, (1985)

← 1 2 3 →